PL3419622T3 - Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny - Google Patents

Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny

Info

Publication number
PL3419622T3
PL3419622T3 PL17757261.7T PL17757261T PL3419622T3 PL 3419622 T3 PL3419622 T3 PL 3419622T3 PL 17757261 T PL17757261 T PL 17757261T PL 3419622 T3 PL3419622 T3 PL 3419622T3
Authority
PL
Poland
Prior art keywords
pridopidine
treatment
eye disease
neurodegenerative eye
neurodegenerative
Prior art date
Application number
PL17757261.7T
Other languages
English (en)
Polish (pl)
Inventor
Hermann Kurt Russ
Michal Geva
Ralph Laufer
Aric ORBACH
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL3419622T3 publication Critical patent/PL3419622T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17757261.7T 2016-02-24 2017-02-24 Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny PL3419622T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662299290P 2016-02-24 2016-02-24
PCT/US2017/019266 WO2017147366A1 (en) 2016-02-24 2017-02-24 Treatment of neurodegenerative eye disease using pridopidine

Publications (1)

Publication Number Publication Date
PL3419622T3 true PL3419622T3 (pl) 2024-07-08

Family

ID=59686581

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17757261.7T PL3419622T3 (pl) 2016-02-24 2017-02-24 Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny

Country Status (10)

Country Link
US (1) US11738012B2 (enExample)
EP (1) EP3419622B1 (enExample)
JP (1) JP7034488B2 (enExample)
AU (1) AU2017223838B2 (enExample)
CA (1) CA3015512C (enExample)
DK (1) DK3419622T3 (enExample)
ES (1) ES2979123T3 (enExample)
HU (1) HUE066769T2 (enExample)
PL (1) PL3419622T3 (enExample)
WO (1) WO2017147366A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
US20220062255A1 (en) * 2016-02-24 2022-03-03 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
BR112019003731A2 (pt) 2016-08-24 2019-07-16 Prilenia Therapeutics Dev Ltd aplicação de pridopidina para tratamento de distonias
JP6912574B2 (ja) 2016-08-24 2021-08-04 プリレニア ニューロセラピューティクス リミテッド 機能低下を治療するためのプリドピジンの使用
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
MX383462B (es) 2017-09-08 2025-03-14 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12357624B2 (en) 2019-02-04 2025-07-15 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for Parkinson's Disease and other diseases associated with parkinsonism
CA3128250C (en) * 2019-03-15 2024-01-16 Michael Hayden Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
JP2024536181A (ja) * 2021-10-11 2024-10-04 プリレニア ニューロセラピューティクス リミテッド 神経変性眼疾患を治療するためのプリドピジン及びその類似体

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
AU2005293754B2 (en) 2004-10-13 2011-07-21 Teva Pharmaceuticals International Gmbh Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
BRPI0810161A2 (pt) 2007-04-12 2014-12-30 Nsab Af Neurosearch Sweden Ab Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
CA2688439A1 (en) 2007-05-31 2008-12-11 Joseph Weinstock Treatment of age-related macular degeneration
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
EA201390332A1 (ru) 2010-09-03 2013-08-30 Ивакс Интернэшнл Гмбх Дейтерированные аналоги придопидина, применимые в качестве допаминергических стабилизаторов
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
EA027748B1 (ru) 2012-04-04 2017-08-31 Тева Фармасьютикалз Интернэшнл Гмбх Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения
CA2884260A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
WO2014205229A1 (en) 2013-06-21 2014-12-24 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease
HUE058288T2 (hu) 2014-01-22 2022-07-28 Prilenia Neurotherapeutics Ltd Pridopidin módosított hatóanyag-leadású készítményei
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
KR20200031446A (ko) 2018-09-14 2020-03-24 삼성전자주식회사 무선 통신 시스템에서 pdcch 모니터링 방법 및 장치

Also Published As

Publication number Publication date
ES2979123T3 (es) 2024-09-24
EP3419622A1 (en) 2019-01-02
CA3015512A1 (en) 2017-08-31
EP3419622A4 (en) 2019-07-10
CA3015512C (en) 2024-01-16
US20190046516A1 (en) 2019-02-14
HUE066769T2 (hu) 2024-09-28
EP3419622B1 (en) 2024-03-06
US11738012B2 (en) 2023-08-29
JP7034488B2 (ja) 2022-03-14
AU2017223838A1 (en) 2018-09-06
AU2017223838B2 (en) 2022-09-29
WO2017147366A1 (en) 2017-08-31
JP2019507758A (ja) 2019-03-22
DK3419622T3 (da) 2024-06-03

Similar Documents

Publication Publication Date Title
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
HUE066769T2 (hu) Neurodegeneratív szembetegség kezelése pridopidinnal
ZA201807084B (en) Methods of treatment of cholestatic diseases
PT3212233T (pt) Terapia combinada para o tratamento de doenças
IL255423A0 (en) Methods for treating neurodegenerative disease
IL269106A (en) Methods for the treatment of neurodegenerative diseases
IL247085A0 (en) Methods for treating Alzheimer's disease
IL246999B (en) Methods for treating Alzheimer's disease
ZA201903003B (en) Treatment of neurological diseases
IL267229A (en) Methods of treating ocular disorders
GB201608046D0 (en) Treatment of complement-mediated disorders
GB201516905D0 (en) Treatment of Neurodegenerative diseases
EP3157631A4 (en) Neurodegenerative disease treatment
GB201412578D0 (en) Treatment of neurological diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
GB201714307D0 (en) Treatment of neurodegenerative diseases
EP3145532A4 (en) Individualized treatment of eye disease
EP3474876A4 (en) TREATMENT OF MORBUS CANAVAN
IL263837A (en) Treatment of ocular disease
GB201411616D0 (en) Diagnosis and treatment of neurodegenerative disorders
GB201714303D0 (en) Treatment of neurodegenerative diseases
GB201714311D0 (en) Treatment of neurodegenerative diseases
GB201604359D0 (en) Treatment of tissue disorders
SI3903774T1 (sl) N,N-bis-2-merkaptoetil izoftalamid za zdravljenje nevrodegenerativnih bolezni
GB201610938D0 (en) Treatment of ocular disease